Novartis, a leader in rheumatology and immuno─dermatology, announced that the European Commission (EC) has approved a label update for the up─titration of Cosentyx (secukinumab) to 300 mg for patients with active
Novartis, a leader in rheumatology and immuno─dermatology, announced that the European Commission (EC) has approved a label update for the up─titration of Cosentyx (secukinumab) to 300 mg for patients with active
Pharmamarketeer richt zich op marketingprofessionals van farmaceuten en andere medisch-gerelateerde organisaties in Nederland en België.
Copyright 2023 © Uitgave van MedHealth Communications BV | Privacy disclaimer
